The Daily Toke

July 19, 2026

# THC & Politics: Federal Legalization Moves Forward as States Chart Competing Courses

A coalition of hemp businesses sued Missouri this week to block a statewide ban on intoxicating hemp products set to take effect November 12, arguing the legislation contains "unconstitutionally vague" definitions that leave businesses, law enforcement, and prosecutors confused about what's actually illegal. The lawsuit, filed in U.S. District Court for the Western District, names Governor Mike Kehoe, Attorney General Catherine Hanaway, and the director of the Missouri Department of Health and Senior Services as defendants. MNG 2005, Inc.—parent company of 55 CBD Kratom stores nationwide—joined the Missouri Hemp Trade Association and Wisconsin-based Lifted Liquids Inc. in the challenge. 💰 MONEY MOVES The legislation would eliminate a product category currently sold in smoke shops with THC concentrations as high as 1,000 mg, removing a revenue stream that exists entirely outside Missouri's licensed marijuana dispensary system. Rep. Dave Hinman, the Republican sponsor of the ban, framed the lawsuit as a "Hail Mary" effort, arguing the bill was thoroughly vetted through both chambers and aligns state law with an upcoming federal ban Congress approved last year.

Meanwhile, 17 Senate Democrats filed legislation this week to fully legalize marijuana under federal law, moving in the opposite direction from the Trump administration's approach of merely reclassifying cannabis. The competing federal strategies reveal a deepening split: one path leads toward comprehensive legalization and a regulated national market; the other toward rescheduling within the existing prohibition framework. 🤔 THINK ABOUT IT Cannabis has never caused a recorded overdose death in human history, while alcohol kills approximately 95,000 Americans annually and prescription opioids kill over 16,000 per year—yet one remains federally prohibited while the other two remain legal and heavily marketed. The Senate bill represents the most direct challenge to Schedule I status in decades, though its prospects in a divided Congress remain uncertain.

State-level momentum continues unevenly. Virginia just legalized recreational cannabis sales, joining a growing number of states moving toward adult-use markets. However, Pennsylvania's adult-use legalization appears stalled again after years of failed attempts, and a medical cannabis initiative in Idaho fell short of qualifying for the general election ballot, leaving that state among the most restrictive in the nation. 🚀 THIS IS COOL The patchwork reflects genuine policy experimentation at the state level—some jurisdictions are building functional regulatory systems that generate tax revenue and prevent unregulated markets, while others maintain blanket prohibitions despite constituent demand.

The Missouri lawsuit highlights a specific tension: when federal law bans intoxicating hemp products but states maintain different rules, businesses face legal landmines. Craig Katz, government relations manager for MNG 2005, noted that lawmakers often lack understanding of cannabis industry mechanics, resulting in legislation that "doesn't make a whole heck of a lot of sense." The bill's definitions allegedly classify identical products as both "hemp" and "marijuana" depending on the provision, creating enforcement chaos. Without clarity, smoke shops operating legally today could face felony charges in November, and law enforcement won't know which products to seize.

The federal Democrats' legalization bill stands in sharp contrast to state-level bans like Missouri's, which align with federal prohibition rather than push against it. If Congress passes federal legalization, states like Missouri would face a choice: maintain bans despite federal legality, or align with the new national standard. The lawsuit may resolve before that reckoning arrives—but it signals that the hemp and cannabis industry is prepared to fight vague state restrictions in federal court, especially when those restrictions eliminate legal products currently generating revenue and serving consumers, including veterans using THC for PTSD and chronic pain management.

July 19, 2026

# Cannabis Industry Posts Profitable Q1 2026 as Federal Rescheduling Unlocks Tax Relief

The cannabis industry's largest operators reported their strongest quarterly earnings in years during the first quarter of 2026, marking the first reporting season where federal tax relief from Schedule III rescheduling reshaped the fundamental economics of doing business. Trulieve Cannabis reported $287 million in revenue with a 59% gross margin and $100 million in adjusted EBITDA at a 35% margin—margins that rival well-run consumer packaged goods companies. Curaleaf Holdings posted $324.2 million in revenue and swung to $70.1 million in net income from continuing operations, ending a multi-quarter losing streak that had defined the sector since 2023. 💰 MONEY MOVES The four largest MSOs by revenue collectively reported approximately $1.8 billion in Q1 2026 revenue, a 12% increase over the same period last year, as the 280E tax deduction prohibition that had crushed operator margins for six years finally lifted for state-licensed medical operations.

The catalyst was the Department of Justice and DEA Final Order signed on April 22, 2026, moving marijuana contained in FDA-approved drug products and marijuana subject to a state-issued medical license from Schedule I to Schedule III of the Controlled Substances Act. That single regulatory shift restored access to ordinary business deductions—wages, rent, marketing, depreciation—that had been barred under Internal Revenue Code Section 280E since the 1980s. The effective federal tax rate for cannabis operators had hovered in the 70-75% range because the IRS forced companies to pay federal income tax on gross profit rather than net income. 🚀 THIS IS COOL The Treasury Department announced on April 23 that the rescheduling applies for the full taxable year that includes the effective date, meaning 280E relief effectively applies from January 1, 2026 forward for qualifying medical operations, potentially dropping effective tax rates to the standard 21% corporate rate. Trulieve generated $56 million in cash flow from operations and $42 million in free cash flow during the quarter, ending with $353 million in cash on the balance sheet—cash that would have vanished into IRS payments under the old regime.

Trulieve's footprint anchors the company's advantage. It operates 240 retail dispensaries and over four million square feet of cultivation and processing capacity across the United States, making it the largest U.S. MSO by store count. The company has filed DEA registration applications for 206 of its state-licensed medical retail locations, positioning itself to scale operations as the federal framework clarifies. Curaleaf, which operates 164 dispensaries and 15 cultivation sites across 15 states, expanded internationally in the quarter, generating $47.2 million in revenue from Europe, Australasia, and North America—up 35 percent year-over-year. The company completed acquisition of German medical cannabis producer Four 20 Pharma and became the first cannabis company to secure registration for standardized cannabis preparations in Spain. Curaleaf also moved to the Toronto Venture Exchange in July 2026, a milestone reflecting growing market maturity and expanded hedging strategies available to institutional investors.

The earnings momentum triggered a remarkable equity rally. The AdvisorShares Pure US Cannabis ETF (MSOS) gained 11.2% in the five trading days ending June 6, 2026, marking its best weekly close since October 2025, with Curaleaf and Trulieve posting gains exceeding 15%. Green Thumb Industries advanced 12.8%. Trading volume across the top ten MSOs by market cap increased 47% week-over-week. The DEA confirmed on June 3 that the final rescheduling rule remains on track for Federal Register publication by August 2026, which would trigger IRC 280E relief for cannabis operators beginning in tax year 2027 and unlock an estimated $1.8 billion annually in excess federal tax liability relief across the sector. Several tier-one MSOs issued upward Q2 2026 revenue guidance during the first week of June—Curaleaf raised its Q2 forecast to $345-$355 million, and Green Thumb increased its Q2 EBITDA projection to $125-$130 million.

🤔 THINK ABOUT IT The U.S. legal cannabis market is projected to surpass $45 billion in annual revenue by 2026. For investors managing an estimated $15 billion in deployed cannabis capital, these earnings reports represent the single most important data source for understanding a $30 billion state-legal industry. Six years into federal prohibition, the companies that survived the "culling of the herd" through balanced expansion and disciplined unit economics are now generating the kind of profitability metrics that had seemed impossible under 280E tax treatment. The policy moment matters. Adult-use and recreational marijuana remain Schedule I, leaving 280E fully in effect for those operations and creating cost allocation complexity for dual-license MSOs. But for medical operators anchored in states like Florida, Pennsylvania, Massachusetts, Arizona, Illinois, and New Jersey, the rescheduling order has reset the table entirely—and the Q1 2026 earnings season is the first evidence that the reset is real.

July 19, 2026

# Hemp Ban Watch: Federal Redefinition Set to Upend $28 Billion Industry

Federal legislation signed by President Trump in November 2025 will effectively ban most intoxicating hemp products starting November 12, 2026—closing a seven-year loophole that transformed hemp into a massive, largely unregulated market. The Continuing Appropriations Act, 2026 (P.L. 119-37) rewrites the federal definition of "hemp" by replacing the 2018 Farm Bill's delta-9 THC threshold with a strict "total THC" standard that includes THCA, delta-8, delta-10, and other cannabinoids. Under the new rules, finished hemp products are capped at just 0.4 milligrams of total THC per container—a ceiling so restrictive that an estimated 90 to 95 percent of products currently on shelves will become federally unlawful. For context: typical delta-8 gummies and vapes on the market today contain between 2.5 and 10 milligrams of THC per unit, making them noncompliant overnight.

💰 MONEY MOVES The impact on the hemp sector is staggering. As of 2025, the intoxicating hemp market was valued at approximately $28.4 billion annually, supported an estimated 300,000 jobs, and generated roughly $1.5 billion in state tax revenue. That entire ecosystem was built on the 2018 Farm Bill's narrow definition—which only restricted delta-9 THC to 0.3 percent by dry weight but said nothing about other psychoactive cannabinoids. Companies quickly discovered they could extract CBD from legal hemp, convert it into delta-8 and other intoxicating compounds, and sell these products nationwide, even in states where recreational cannabis remained illegal. The loophole was so expansive that by 2025, hemp-derived THC products flooded convenience stores, gas stations, smoke shops, and e-commerce platforms across America. Now, with one year until enforcement begins, operators, farmers, and industry stakeholders face either shutdown, inventory destruction, or urgent lobbying for legislative delay.

The new law explicitly bans synthetic and lab-converted cannabinoids—delta-8, delta-10, HHC, and similar compounds derived through isomerization or chemical modification—while also targeting high-THCA flower and products. Even "full spectrum" CBD products, which contain trace amounts of naturally occurring cannabinoids, will exceed the 0.4-milligram container limit. The FDA is directed to publish a list of naturally occurring cannabinoids within 90 days of the Act's enactment, but the regulatory groundwork offers little comfort to an industry suddenly facing illegality. The law does preserve a carve-out for industrial hemp cultivated for fiber, grain, oil, seeds, microgreens, and research—the original intent of the 2018 Farm Bill—but the container limit is so restrictive that it effectively eliminates most commercial cannabinoid products regardless of their source or potency claims.

State-level advocacy has intensified in response. In October 2025, a bipartisan coalition of 39 state and territory attorneys general sent a letter to Congress urging closure of the Farm Bill loophole, citing concerns about unregulated products and consumer safety. Their push succeeded. Yet some industry voices and lawmakers have already begun circulating proposals to delay the ban's effective date from November 2026 to November 2028, arguing that a two-year extension would give farmers, retailers, and manufacturers time to adapt. 🤔 THINK ABOUT IT The federal government is moving to restrict a zero-overdose product while alcohol—which kills approximately 95,000 Americans per year—remains legal and aggressively marketed. Prescription opioids, which kill 16,000-plus Americans annually, face far less categorical restriction. Cannabis has never caused a recorded overdose death in human history. Yet Schedule I classification—a designation more restrictive than heroin in the eyes of federal law—persists for hemp-derived THC products. The contradiction is worth examining.

Veterans and chronic pain patients face particular consequences. Many service members use legal hemp-derived THC products to manage PTSD, anxiety, and chronic pain in states where medical and recreational cannabis remain illegal. The November 2026 deadline forces them into a narrowed choice set: transition to state-legal programs in jurisdictions that have legalized cannabis, navigate unregulated black markets, or rely on prescription pharmaceuticals with documented addiction and overdose risks. The ban's timing also matters: industry sources and legal analysts have been clear that the November 12, 2026 enforcement date is firm unless Congress acts to modify or delay it. Any legislative reversal or postponement would require affirmative action in the House and Senate, signed into law before the deadline arrives. For now, the clock is running. The hemp sector has one year to comply, lobby for change, or prepare for the largest federal cannabis product seizure in modern American history.

July 19, 2026

# THC in Science

Federal regulators are moving methodically through the cannabis research landscape as new clinical evidence emerges on therapeutic applications once dismissed as fringe science. The FDA's Cannabis Product Committee continues developing cross-agency strategy for regulating cannabis-derived compounds, even as the agency acknowledges significant knowledge gaps about safety and efficacy. Marinol and Syndros, both synthetic delta-9-tetrahydrocannabinol products, remain FDA-approved medicines, yet the agency is simultaneously grappling with how to regulate cannabidiol and other hemp-derived compounds flooding the market with minimal oversight. The regulatory framework that took decades to establish for these synthetic THC medications now faces pressure to accommodate whole-plant cannabis science that's accelerating faster than policy can follow.

🚀 THIS IS COOL A recent Lancet Psychiatry study published in March 2026 concluded that a combination of cannabidiol and delta-9-tetrahydrocannabinol reduced cannabis withdrawal symptoms and decreased cannabis use among study participants—suggesting that THC itself, when properly formulated and measured, may have clinical utility beyond the "abuse potential" narrative that has dominated policy discussions for generations. Meanwhile, active research into CBD's role in reducing inflammation biomarkers at the cellular level, particularly in HIV-positive populations, is underway at major university research centers. These are not speculative outcomes or rodent studies; these are clinical investigations happening in peer-reviewed journals and NIH-registered trials.

A current clinical trial registered at NIH is specifically assessing cognition and neural function in chronic pain patients prescribed medical cannabis, examining drug exposure and behavioral outcomes with scientific rigor typically reserved for pharmaceutical development. The Consortium for Medical Marijuana Clinical Outcomes Research released its sixth annual report this year and is now accepting abstracts for its annual conference in Orlando, with 28 full proposals currently under review for 2026 grant funding. 💰 MONEY MOVES The Consortium received 34 letters of interest from faculty across eight member institutions, reflecting genuine institutional investment in establishing what researchers call the "clinical outcomes" evidence base—the before-and-after documentation of how THC and cannabinoid products actually perform in real patients.

The FDA's own public health focus pages acknowledge that chronic pain and mental health conditions are among the top reasons people seek medical cannabis, yet the agency simultaneously warns consumers about accidental pediatric ingestion of THC edibles and continues classifying cannabis as Schedule I—a classification that legally means the substance has no accepted medical use. 🤔 THINK ABOUT IT That same classification system permits the approval and marketing of synthetic THC pharmaceuticals like dronabinol while technically declaring the plant itself medically worthless. The gap between FDA actions and FDA policy language reveals an agency managing a contradiction that science has outpaced: the regulatory apparatus built to prevent harm is now managing products with documented therapeutic signal, yet the scheduling structure won't accommodate that evidence.

What's happening in late 2026 is a quiet professionalization of cannabis research. These aren't advocacy organizations conducting studies; they're university consortiums, NIH-registered trials, and peer-reviewed publications following standard clinical methodology. The evidence is accumulating in real time, documented in medical journals and presented at conferences with the same rigor as any other pharmaceutical research. The regulatory question is no longer whether THC has biological effects—that was settled decades ago with Marinol's approval—but whether the research infrastructure and policy framework can evolve fast enough to accommodate what the science is already demonstrating.

July 19, 2026

Texas hemp retailers and manufacturers face an uncertain future after the state's Fifteenth Court of Appeals cleared the way for strict new rules governing smokable cannabis products to take effect again, though state regulators remain unclear about whether they'll actually enforce them. The appeals court on Friday denied the hemp industry's emergency request to keep a temporary injunction in place that had blocked the Texas Department of State Health Services from enforcing major portions of new regulations while litigation continues. A Department of State Health Services spokesperson told KUT that the agency is "still determining how to proceed given that there is not a final disposition yet," leaving the state's hemp market in legal limbo even as the court order technically allows enforcement to resume.

At the center of the dispute is the "Total THC Rule," a March 2026 regulation that dramatically changed how Texas measures THC content in hemp products. The new rule counts THCA—a non-intoxicating cannabinoid that converts to Delta-9 THC when heated—as 88% Delta-9 for regulatory purposes, effectively banning most smokable hemp flower and concentrates overnight. 💰 MONEY MOVES The impact has been severe: retailers and manufacturers lost the majority of their product inventory, and small shops face potential shutdown if they can't quickly reformulate their stock to comply with the new calculations. Lukas Gilkey, CEO of Hometown Hero, an Austin-based hemp retailer and head of the Texas Hemp Business Council leading the legal challenge, acknowledged the chaos: "I know it's been a lot of crazy back and forth and the lawyers are doing their best to push this forward and keep this going. This is really going to impact the small stores."

The legal back-and-forth traces back to May 2025, when the Texas Legislature passed Senate Bill 3, a sweeping bill that would have banned the sale and possession of all hemp-derived products containing any amount of THC. Governor Greg Abbott vetoed the measure in June 2025, calling for regulation instead of prohibition, and the Legislature reached a stalemate during two special sessions on the matter. Instead of waiting for legislative resolution, the Department of State Health Services unilaterally rewrote hemp regulations in December 2025 and implemented them March 31, 2026, prompting the hemp industry coalition to sue, arguing the agency exceeded its authority. A Travis County judge granted a temporary restraining order on April 8, blocking enforcement and temporarily restoring the interstate shipping of smokable hemp—but that protection lasted just weeks before the appeals court reversed it.

Under Texas law, recreational marijuana remains firmly illegal: possession of up to two ounces is a Class B misdemeanor punishable by up to 180 days in prison and a $2,000 fine. Austin has attempted to soften enforcement through a voter-approved 2022 ordinance limiting police citations for small amounts, but the state successfully challenged that policy in April 2025, leaving residents with legal risk regardless of local police discretion. Meanwhile, edibles, gummies, and beverages containing hemp-derived Delta-9 THC remain fully legal as long as they comply with the 0.3% Delta-9 THC by dry weight federal standard—a critical distinction that means consumers can access some cannabis products legally while others face criminal jeopardy depending on how they're ingested.

The case returns to court on April 28, 2026, with potential testimony extending through April 30, where judges will finally decide whether DSHS had the authority to rewrite definitions the Legislature had already established. 🤔 THINK ABOUT IT Texas has spent months in regulatory ping-pong over hemp products that contain zero recorded overdose deaths in human history, while alcohol kills roughly 95,000 Americans annually and prescription opioids kill over 16,000—both remain legal and heavily regulated. For now, THCa flower remains on shelves at licensed retailers in Austin and across Texas only because of the court's temporary order, not because state regulators have decided the products should be legal.